The global biologics safety testing market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period. The growth of the global biologics safety testing market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination, and rising biopharmaceuticals R&D activities and investments. In addition, emerging markets and increasing biopharmaceutical outsourcing are expected to provide significant growth opportunities for players in the Biologics safety testing market.
By product segment, the service segment accounted for the largest share of the Biologics Safety Testing market Based on product and service, the biologics safety testing market is segmented into consumables, services, and instruments.In 2020, the services segment accounted for the largest market share.
The large share of this segment can be attributed to the limited finances of biopharmaceutical manufacturers, capacity constraints, need for reduction in the time to market, complex manufacturing requirements, large investments required for establishing manufacturing facilities, and the increasing drugs pipeline, all of which have prompted the shift towards the outsourcing of biologics safety testing to service providers. ”By application, the monoclonal antibodies manufacturing segment accounted for the largest market share of the Biologics safety testing market “ Based on application, the biologics safety testing market is segmented into monoclonal antibodies manufacturing, vaccines manufacturing, blood and blood products manufacturing, cellular and gene therapy products manufacturing, and other applications.In 2020, the monoclonal antibodies manufacturing segment accounted for the largest market share.
The large share of this segment can be attributed to the rising prevalence of diseases and increasing government initiatives for the development of monoclonal antibody drugs.
Asia Pacific: The fastest-growing region in the Biologics Safety Testing Market The Biologics Safety Testing Market in the Asia Pacific region is projected to register the highest growth during the forecast period. Factors such as growing R&D funding, rising product availability, lower outsourcing costs, increasing research activities, increasing applications of oligos in molecular diagnostics & therapeutics, and the rising awareness of oligonucleotides are expected to drive market growth.
North America accounted for the largest share of the Biologics safety testing market in 2020 North America accounted for the largest share of the biologics safety testing market in 2020.Rapid growth in the biopharmaceutical industry is the major factor driving the growth of the North American biologics safety testing market.
Growing academic and government investments, rising demand for high-quality research tools for data reproducibility, increasing awareness among consumers about product safety, and the presence of major market players in this region are also driving the market for biologics safety testing in North America.
Breakdown of primaries The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows: • By Respondent– Supply Side- 80%, Demand Side-20% • By Designation— CXOs- 20%, Executives - 25%, Mangers - 55% • By Region— North America -40%, Europe - 30%, APAC – 20%, LATAM & MEA- 10%
The Biologics Safety Testing market is dominated by a few globally established players such Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and SGS SA (Switzerland), Eurofins Scientific (Luxembourg), Maravai Lifesciences (US), Associates of Cape Cod, Inc. (US), bioMérieux SA (France), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Nelson Laboratories, LLC (US), Bio-Rad Laboratories, Inc. (US) and QIAGEN (Germany),Agilent Technologies, Inc. (US), Pacific BioLabs (US), Microcoat Biotechnologie GmbH (Germany), PromoCell GmbH (Germany), FUJIFILM Wako Pure Chemical Corporation (Japan), and Almac Group (UK).
Research Coverage: The report segments the Biologics Safety Testing market based on region (Asia Pacific, Europe, North America, Latin America and Middle East and Africa), product and service(consumables, services, and instruments), application(monoclonal antibodies manufacturing, vaccines manufacturing, blood and blood products manufacturing, cellular and gene therapy products manufacturing, and other applications.), and test types(endotoxin tests, sterility tests, mycoplasma tests, bioburden tests, virus safety tests, and residual host-cell proteins and DNA detection tests.). The report also provides a comprehensive review of market drivers, opportunities, challenges and trends in the Biologics Safety Testing market.
Key Benefits of Buying the Report: The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments.This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies.
The report also helps stakeholders understand the pulse of the Biologics Safety Testing market and provides them information on key market drivers, restraints, challenges, and opportunities.
Our reports have been used by over 10K customers, including:
The Global Biologics CDMO Market was valued at USD 9.93 billion in 2020 and is expected to reach USD 18.63 billion by 2026, registering a CAGR of 10.87% during the forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19 pandemic....
The global single-use assemblies market is projected to reach USD 6.3 billion by 2026 from USD 2.2 billion in 2021, at a CAGR of 23.3% during the forecast period. The growth of the single-use assemblies market can primarily be attributed to the major advantages of single-use technologies as compared to traditional stainless-steel assemblies,...
The solvent evaporation market was valued at US$ 470.77 million in 2020 and it is projected to reach US$ 821.41 million by 2028; it is expected to grow at a CAGR of 6.7% during 2021–2028. The factors such as increasing expenditure on R&D, growing development of large-molecule biopharmaceuticals, and surging demand for pure samples in...
243 pages •
By Asia Market Information & Development Company
• Apr 2021
China’s demand for Biologics has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
Executive Summary Global Biologics Safety Testing Market was valued at USD 3463.90 Million in the year 2020. Major factors driving the growth of this market are the growth in pharmaceutical and biotechnology industry driven by government support, the positive trend of R&D investment in the life science sector, increasing...
The microcarriers market is projected to reach USD 2.9 billion by 2026 from USD 1.7 billion in 2021, at a CAGR of 10.7% during the forecast period. Increasing use of single-use bioreactors for bioprocessing, rising investmnet in R&D for developemnt of vaccines and therapeutic protiens, and increasing government funding for cell and gene therapy. •...
The microcarrier market is majorly driven by factors such as rising demand for cell-based vaccines and therapeutics, the rapid growth of biologics and biosimilar industry, and increasing R&D and availability of funding for cell therapy research. Many of the current biologics in the pipeline are targeting the indications, which are small-molecule...
The global recombinant proteins market is projected to reach USD 1.7billion by 2026 from USD 1.0billion in 2021, at a CAGR of 9.8% during the forecast period. The market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies, growing industryacademia collaborations,...
The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period. The protein A resin market has witnessed increasing consumption due to increased monoclonal antibody production on account of the pandemic situation worldwide.. Growth in the market can primarily...
The fill finish manufacturing market was valued at US$ 6,129.03 million in 2019 and is projected to reach US$ 12,547.23 million by 2027; it is expected to grow at a CAGR of 9.6% from 2020 to 2027. The growth of the fill finish manufacturing market is mainly attributed to factors such as rising adoption of prefilled syringes for parenteral...
Chronic Disease Prevalence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.